Abdominal Aortic Aneurysm Metformin Trial

Monday, March 15, 2021

Eastern Health Clinical School Associate Professor Anthony Dear, is leading a trial in to the commonly used Type 2 Diabetes drug, Metformin, to see if its use could prevent or reduce the need for surgery in patients with the life threatening condition, Abdominal Aortic Aneurysm (AAA).



Abdominal Aortic Aneurysm (AAA) affects about 20 million people and causes 200,000 deaths worldwide each year. However, research has found AAAs are less common in patients with diabetes.

The multi-centre randomised placebo controlled trial will investigate if Metformin's anti-inflammatory effects reduce AAA growth and help to prevent rupture. At the moment, high-risk surgery is the only treatment available.

"Our hope for the trial is to establish if Metformin cannot only prevent the need for surgery, but prevent any further growth and rupture,” Associate Professor Dear said.

The trial, involving 2000 patients, is taking place across Australia, New Zealand, Sweden and the UK and is being supported by Monash University, The George Institute for Global Health, National Health and Medical Research Council Australia (NHMRC) and Australia's James Cook University.

For more information about the trial, click here